Financhill
Sell
46

HOCPY Quote, Financials, Valuation and Earnings

Last price:
$114.54
Seasonality move :
4.16%
Day range:
$110.90 - $115.99
52-week range:
$97.49 - $148.27
Dividend yield:
0.96%
P/E ratio:
29.66x
P/S ratio:
6.77x
P/B ratio:
6.03x
Volume:
16.4K
Avg. volume:
29.9K
1-year change:
-6.11%
Market cap:
$39.3B
Revenue:
$5.8B
EPS (TTM):
$3.86

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HOCPY
Hoya
-- -- -- -- --
AMGXF
AnGes
-- -- -- -- --
HLOSF
Healios KK
-- -- -- -- --
PPTDF
PeptiDream
-- -- -- -- --
SOLTF
Nxera Pharma
-- -- -- -- --
TAK
Takeda Pharmaceutical
$8.1B -- 2.75% -- $17.15
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HOCPY
Hoya
$114.54 -- $39.3B 29.66x $0.80 0.96% 6.77x
AMGXF
AnGes
$0.36 -- $117.8M -- $0.00 0% 22.97x
HLOSF
Healios KK
$3.17 -- $321.6M -- $0.00 0% 76.64x
PPTDF
PeptiDream
$13.53 -- $1.8B 16.80x $0.00 0% 5.80x
SOLTF
Nxera Pharma
$7.00 -- $629.3M -- $0.00 0% 3.51x
TAK
Takeda Pharmaceutical
$14.96 $17.15 $46.7B 68.56x $0.33 4.13% 1.60x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HOCPY
Hoya
3.69% 0.526 0.64% 4.01x
AMGXF
AnGes
-- 1.166 -- 1.28x
HLOSF
Healios KK
51.17% -0.602 6.95% 1.11x
PPTDF
PeptiDream
25.74% 0.569 5.48% 4.62x
SOLTF
Nxera Pharma
48.1% 1.893 78.18% 2.83x
TAK
Takeda Pharmaceutical
39.43% -0.370 64.47% 0.45x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HOCPY
Hoya
$1.3B $819.7M 19.62% 20.47% 29.07% $385.2M
AMGXF
AnGes
$368.5K -$8.2M -33.92% -33.92% -741.83% --
HLOSF
Healios KK
$59K -$4.9M -85.83% -196.15% -1239.47% -$5.1M
PPTDF
PeptiDream
$9.6M -$9M 23.58% 34.1% -29.18% -$69.4M
SOLTF
Nxera Pharma
$33M -$14.4M -4.28% -8.65% -28.7% -$14.8M
TAK
Takeda Pharmaceutical
$4.4B -$491.4M 0.89% 1.49% -5.41% $854.8M

Hoya vs. Competitors

  • Which has Higher Returns HOCPY or AMGXF?

    AnGes has a net margin of 22.37% compared to Hoya's net margin of -737.34%. Hoya's return on equity of 20.47% beat AnGes's return on equity of -33.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    HOCPY
    Hoya
    87.29% $0.95 $6.7B
    AMGXF
    AnGes
    33.2% -$0.03 $21.5M
  • What do Analysts Say About HOCPY or AMGXF?

    Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Hoya has higher upside potential than AnGes, analysts believe Hoya is more attractive than AnGes.

    Company Buy Ratings Hold Ratings Sell Ratings
    HOCPY
    Hoya
    0 0 0
    AMGXF
    AnGes
    0 0 0
  • Is HOCPY or AMGXF More Risky?

    Hoya has a beta of 0.911, which suggesting that the stock is 8.893% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HOCPY or AMGXF?

    Hoya has a quarterly dividend of $0.80 per share corresponding to a yield of 0.96%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoya pays 19.01% of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HOCPY or AMGXF?

    Hoya quarterly revenues are $1.5B, which are larger than AnGes quarterly revenues of $1.1M. Hoya's net income of $331M is higher than AnGes's net income of -$8.2M. Notably, Hoya's price-to-earnings ratio is 29.66x while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 6.77x versus 22.97x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HOCPY
    Hoya
    6.77x 29.66x $1.5B $331M
    AMGXF
    AnGes
    22.97x -- $1.1M -$8.2M
  • Which has Higher Returns HOCPY or HLOSF?

    Healios KK has a net margin of 22.37% compared to Hoya's net margin of -6742.11%. Hoya's return on equity of 20.47% beat Healios KK's return on equity of -196.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    HOCPY
    Hoya
    87.29% $0.95 $6.7B
    HLOSF
    Healios KK
    23.68% -$0.18 $26.9M
  • What do Analysts Say About HOCPY or HLOSF?

    Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Hoya has higher upside potential than Healios KK, analysts believe Hoya is more attractive than Healios KK.

    Company Buy Ratings Hold Ratings Sell Ratings
    HOCPY
    Hoya
    0 0 0
    HLOSF
    Healios KK
    0 0 0
  • Is HOCPY or HLOSF More Risky?

    Hoya has a beta of 0.911, which suggesting that the stock is 8.893% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HOCPY or HLOSF?

    Hoya has a quarterly dividend of $0.80 per share corresponding to a yield of 0.96%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoya pays 19.01% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HOCPY or HLOSF?

    Hoya quarterly revenues are $1.5B, which are larger than Healios KK quarterly revenues of $249.2K. Hoya's net income of $331M is higher than Healios KK's net income of -$16.8M. Notably, Hoya's price-to-earnings ratio is 29.66x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 6.77x versus 76.64x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HOCPY
    Hoya
    6.77x 29.66x $1.5B $331M
    HLOSF
    Healios KK
    76.64x -- $249.2K -$16.8M
  • Which has Higher Returns HOCPY or PPTDF?

    PeptiDream has a net margin of 22.37% compared to Hoya's net margin of -24.41%. Hoya's return on equity of 20.47% beat PeptiDream's return on equity of 34.1%.

    Company Gross Margin Earnings Per Share Invested Capital
    HOCPY
    Hoya
    87.29% $0.95 $6.7B
    PPTDF
    PeptiDream
    34.69% -$0.05 $493M
  • What do Analysts Say About HOCPY or PPTDF?

    Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Hoya has higher upside potential than PeptiDream, analysts believe Hoya is more attractive than PeptiDream.

    Company Buy Ratings Hold Ratings Sell Ratings
    HOCPY
    Hoya
    0 0 0
    PPTDF
    PeptiDream
    0 0 0
  • Is HOCPY or PPTDF More Risky?

    Hoya has a beta of 0.911, which suggesting that the stock is 8.893% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

  • Which is a Better Dividend Stock HOCPY or PPTDF?

    Hoya has a quarterly dividend of $0.80 per share corresponding to a yield of 0.96%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoya pays 19.01% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HOCPY or PPTDF?

    Hoya quarterly revenues are $1.5B, which are larger than PeptiDream quarterly revenues of $27.8M. Hoya's net income of $331M is higher than PeptiDream's net income of -$6.8M. Notably, Hoya's price-to-earnings ratio is 29.66x while PeptiDream's PE ratio is 16.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 6.77x versus 5.80x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HOCPY
    Hoya
    6.77x 29.66x $1.5B $331M
    PPTDF
    PeptiDream
    5.80x 16.80x $27.8M -$6.8M
  • Which has Higher Returns HOCPY or SOLTF?

    Nxera Pharma has a net margin of 22.37% compared to Hoya's net margin of -11.44%. Hoya's return on equity of 20.47% beat Nxera Pharma's return on equity of -8.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    HOCPY
    Hoya
    87.29% $0.95 $6.7B
    SOLTF
    Nxera Pharma
    75.69% -$0.06 $863.6M
  • What do Analysts Say About HOCPY or SOLTF?

    Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Hoya has higher upside potential than Nxera Pharma, analysts believe Hoya is more attractive than Nxera Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    HOCPY
    Hoya
    0 0 0
    SOLTF
    Nxera Pharma
    0 0 0
  • Is HOCPY or SOLTF More Risky?

    Hoya has a beta of 0.911, which suggesting that the stock is 8.893% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.360, suggesting its less volatile than the S&P 500 by 64.028%.

  • Which is a Better Dividend Stock HOCPY or SOLTF?

    Hoya has a quarterly dividend of $0.80 per share corresponding to a yield of 0.96%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoya pays 19.01% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HOCPY or SOLTF?

    Hoya quarterly revenues are $1.5B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Hoya's net income of $331M is higher than Nxera Pharma's net income of -$5M. Notably, Hoya's price-to-earnings ratio is 29.66x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 6.77x versus 3.51x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HOCPY
    Hoya
    6.77x 29.66x $1.5B $331M
    SOLTF
    Nxera Pharma
    3.51x -- $43.6M -$5M
  • Which has Higher Returns HOCPY or TAK?

    Takeda Pharmaceutical has a net margin of 22.37% compared to Hoya's net margin of -9.79%. Hoya's return on equity of 20.47% beat Takeda Pharmaceutical's return on equity of 1.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    HOCPY
    Hoya
    87.29% $0.95 $6.7B
    TAK
    Takeda Pharmaceutical
    63.73% -$0.21 $76.5B
  • What do Analysts Say About HOCPY or TAK?

    Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.15 which suggests that it could grow by 14.64%. Given that Takeda Pharmaceutical has higher upside potential than Hoya, analysts believe Takeda Pharmaceutical is more attractive than Hoya.

    Company Buy Ratings Hold Ratings Sell Ratings
    HOCPY
    Hoya
    0 0 0
    TAK
    Takeda Pharmaceutical
    3 1 0
  • Is HOCPY or TAK More Risky?

    Hoya has a beta of 0.911, which suggesting that the stock is 8.893% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.227, suggesting its less volatile than the S&P 500 by 77.347%.

  • Which is a Better Dividend Stock HOCPY or TAK?

    Hoya has a quarterly dividend of $0.80 per share corresponding to a yield of 0.96%. Takeda Pharmaceutical offers a yield of 4.13% to investors and pays a quarterly dividend of $0.33 per share. Hoya pays 19.01% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

  • Which has Better Financial Ratios HOCPY or TAK?

    Hoya quarterly revenues are $1.5B, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Hoya's net income of $331M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Hoya's price-to-earnings ratio is 29.66x while Takeda Pharmaceutical's PE ratio is 68.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 6.77x versus 1.60x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HOCPY
    Hoya
    6.77x 29.66x $1.5B $331M
    TAK
    Takeda Pharmaceutical
    1.60x 68.56x $6.9B -$676.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can Planet Labs Go Now?
How High Can Planet Labs Go Now?

Planet Labs (NYSE:PL) has been a much-talked-about stock for years,…

Where Will Broadcom Stock Be in 5 Years?
Where Will Broadcom Stock Be in 5 Years?

Broadcom (NASDAQ:AVGO) has soared by over 75 percent over the…

What Is The Target Price For VRRM Stock?
What Is The Target Price For VRRM Stock?

Verra Mobility Corporation (NASDAQ:VRRM) is in the business of making…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 34x

Alerts

Sell
19
LULU alert for Jun 7

Lululemon Athletica [LULU] is down 19.83% over the past day.

Sell
46
DOCU alert for Jun 7

Docusign [DOCU] is down 18.99% over the past day.

Buy
66
BYRN alert for Jun 7

Byrna Technologies [BYRN] is up 18.03% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock